Combined Hepatocellular-Cholangiocarcinoma Patient Treated with Durvalumab Plus Gemcitabine and Cisplatin: A Case Report.

A 55-year-old man with lower abdominal pain and diarrhea was referred to our hospital. Computed tomography (CT) revealed a hypovascular liver tumor, lymph node/bone metastases, and peritoneal dissemination. Based on a histological analysis of lymph node metastasis, he was diagnosed with combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and received durvalumab plus gemcitabine and cisplatin (Dur/GC). After treatment, the patient developed grade 2 diarrhea and grade 3 thrombocytopenia. CT after one course of Dur/GC demonstrated tumor shrinkage and expanded peritoneal dissemination, suggesting the need for further studies on the efficacy and safety of this therapy for unresectable cHCC-CCA.